✦ LIBER ✦

A phase II trial of didemnin B in myeloma

✍ Scribed by Raymond B. Weiss; Bercedis L. Peterson; Steven L. Allen; Scott M. Browning; David B. Duggan; Charles A. Schiffer

Publisher: Springer US
Year: 1994
Tongue: English
Weight: 272 KB
Volume: 12
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00873234

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of didemnin-B in advanced

Phase II trial of didemnin-B in advanced epithelial ovarian cancer

✍ Joanna M. Cain; P. Y. Liu; David E. Alberts; Holly H. Gallion; Leslie Laufman; J 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 157 KB

A phase i clinical trial of didemnin B

✍ James A. Stewart; Jane B. Low; John D. Roberts; Alton Blow 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 448 KB 👁 2 views

Phase II trial of Didemnin B in patients

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma

✍ Robert Motzer; Howard Scher; Dean Bajorin; Cora Sternberg; George J. Bosl 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 115 KB

Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5070) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell

Phase II clinical trial of didemnin B in

Phase II clinical trial of didemnin B in previously treated small cell lung cancer

✍ Dong M. Shin; Paul Y. Holoye; Arthur Forman; Rodger Winn; Roman Perez-Soler; Sha 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 521 KB

Phase II study of didemnin B in advanced

Phase II study of didemnin B in advanced colorectal cancer

✍ Dennie V. Jones; Jaffer A. Ajani; Roxann Blackburn; Karen Daugherty; Bernard Lev 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 222 KB

Phase II trial of amsacrine in patients

Phase II trial of amsacrine in patients with multiple myeloma

✍ Greipp, Philip R. ;Coleman, Morton ;Anderson, Keaven ;McIntyre, O. Ross 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

Seventy-four previously treated patients with multiple myeloma were treated with Amsacrine (m-AMSA) 120 mg/m2 every 3 weeks. A good response was observed in two patients (3%), and improvement was seen in three patients (4%). Severe toxicity was observed in 33% of patients who received three or more